Atossa Therapeutics logged a 0.3% change during today's morning session, and is now trading at a price of $0.93 per share.
Atossa Therapeutics returned losses of -10.6% last year, with its stock price reaching a high of $1.24 and a low of $0.5. Over the same period, the stock underperformed the S&P 500 index by -26.0%. As of April 2023, the company's 50-day average price was $0.76. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. Based in Seattle, WA, the small-cap Health Care company has 11 full time employees. Atossa Therapeutics has not offered a dividend during the last year.
An Exceptionally Strong Balance Sheet:
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Revenue (k) | $0 | $0 | $0 | $0 |
| Operating Margins | n/a | n/a | n/a | n/a |
| Net Margins | n/a | n/a | n/a | n/a |
| Net Income (k) | -$17,240 | -$17,828 | -$20,606 | -$26,960 |
| Net Interest Expense (k) | n/a | -$939 | n/a | $877 |
| Depreciation & Amort. (k) | -$53 | -$47 | -$23 | -$8 |
| Earnings Per Share | -$2.03 | -$1.97 | -$0.18 | -$0.2 |
| EPS Growth | n/a | 2.96% | 90.86% | -11.11% |
| Diluted Shares (k) | 8,497 | 11,309 | 116,950 | 126,624 |
| Free Cash Flow (k) | -$9,136 | -$11,580 | -$16,481 | -$20,787 |
| Capital Expenditures | -$8 | -$9 | -$9 | -$27 |
| Net Current Assets (k) | $12,985 | $27,099 | $138,114 | $112,629 |
| Current Ratio | 10.83 | 2.73 | 45.18 | 21.23 |
Atossa Therapeutics has an excellent current ratio, weak revenue growth and increasing reinvestment in the business, and a strong EPS growth trend. However, the firm suffers from consistently negative margins with a stable trend and negative cash flows.
Atossa Therapeutics does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at $-0.25. The average P/E ratio for the Health Care sector is 24.45. On the other hand, the market is undervaluing Atossa Therapeutics in terms of its equity because its P/B ratio is 1.04. In comparison, the sector average is 4.16.
Atossa Therapeutics Is the Subject of Mixed Market Indicators:
The 2 analysts following Atossa Therapeutics have set target prices ranging from $4.0 to $5.25 per share, for an average of $4.63 with a buy rating. As of April 2023, the company is trading -83.6% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
Atossa Therapeutics has an average amount of shares sold short because 5.9% of the company's shares are sold short. Institutions own 20.7% of the company's shares, and the insider ownership rate stands at 0.04%, suggesting a small amount of insider investors. The largest shareholder is the Vanguard Group, Inc., whose 4% stake in the company is worth $5,298,708.
